<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211415</url>
  </required_header>
  <id_info>
    <org_study_id>DS2741-A-J101</org_study_id>
    <secondary_id>195071</secondary_id>
    <nct_id>NCT04211415</nct_id>
  </id_info>
  <brief_title>Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis</brief_title>
  <official_title>DS-2741a Phase I Study- A Three-part First-in-human Study: Single Ascending Dose and Multiple Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-2741a After Subcutaneous Injection in Healthy Japanese Male Subjects, and Single Dose Study to Assess the Pharmacokinetics, Safety, Pharmacodynamics and Efficacy of DS-2741a After Subcutaneous Injection in Japanese Subjects With Moderate to Severe Atopic Dermatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, single-center, first-in-human study to assess the safety, pharmacokinetics
      and pharmacodynamics of DS-2741a after subcutaneous injection in healthy Japanese male
      volunteers and Japanese participants with moderate to severe atopic dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of three parts. Part 1 and Part 3 are a single ascending and multiple
      dose study to assess the safety, pharmacokinetics and pharmacodynamics of DS-2741a after
      subcutaneous injection in healthy Japanese male participants. Part 2 is a single-dose study
      to assess the pharmacokinetics, safety, pharmacodynamics and efficacy of DS-2741a after
      subcutaneous injection in Japanese participants with moderate to severe atopic dermatitis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participant, care provider, investigator, and outcomes assessor will be blinded in Part 1 and Part 3 of the study. Part 2 of the study will be unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events among participants receiving DS-2741a (Part 1 and Part 3)</measure>
    <time_frame>Day 1 through end of study, up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize pharmacokinetic parameter maximum plasma concentration (Cmax) of plasma DS-2741a (Part 2)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize pharmacokinetic parameter time to reach maximum plasma concentration (Tmax) of plasma DS-2741a (Part 2)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize pharmacokinetic parameter area under the curve from time 0 to last measurable time point (AUClast) of plasma DS-2741a (Part 2)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize pharmacokinetic parameter area under the curve from time 0 to 168 h (AUC168h) of plasma DS-2741a (Part 2)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize pharmacokinetic parameter total clearance (CL/F) of plasma DS-2741a (Part 2)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize pharmacokinetic parameter area under the curve from time 0 to infinity (AUCinf) of plasma DS-2741a (Part 2)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize pharmacokinetic parameter terminal elimination half-life (t1/2) of plasma DS-2741a (Part 2)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize pharmacokinetic parameter volume of distribution (Vz/F) of plasma DS-2741a (Part 2)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter maximum plasma concentration (Cmax) of plasma DS-2741a (Part 1)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter time to reach maximum plasma concentration (Tmax) of plasma DS-2741a (Part 1)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter area under the curve from time 0 to last measurable time point (AUClast) of plasma DS-2741a (Part 1)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter area under the curve from time 0 to 168 h (AUC168h) of plasma DS-2741a (Part 1)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter total clearance (CL/F) of plasma DS-2741a (Part 1)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter area under the curve from time 0 to infinity (AUCinf) of plasma DS-2741a (Part 1)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4,Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter terminal elimination half-life (t1/2) of plasma DS-2741a (Part 1)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter volume of distribution (Vz/F) of plasma DS-2741a (Part 1)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 11, Day 14, Day 17, Day 21, Day 28, Day 35, Day 42, Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs) against DS-2741a (Part 1 and Part 2)</measure>
    <time_frame>Day 1 (pre-dose), Day 28, Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events among participants receiving DS-2741a (Part 2)</measure>
    <time_frame>Day 1 through end of study, up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter maximum plasma concentration (Cmax) of plasma DS-2741a (Part 3)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 3, Day 5, Day 7 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 10, Day 12, Day 14 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter time to reach maximum plasma concentration (Tmax) of plasma DS-2741a (Part 3)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 3, Day 5, Day 7 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 10, Day 12, Day 14 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter trough plasma concentration (Ctrough) of plasma DS-2741a (Part 3)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 3, Day 5, Day 7 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 10, Day 12, Day 14 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter area under the curve from time 0 to 168 h (AUC168h) of plasma DS-2741a (Part 3)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 3, Day 5, Day 7 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 10, Day 12, Day 14 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter area under the curve from time 0 to tau (504-672 h) (AUCtau) of plasma DS-2741a (Part 3)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 3, Day 5, Day 7 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 10, Day 12, Day 14 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetic parameter terminal elimination half-life (t1/2) of plasma DS-2741a (Part 3)</measure>
    <time_frame>Day 1 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 3, Day 5, Day 7 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 10, Day 12, Day 14 (pre-dose, 2, 8, 24, 36 hours after the start of administration), Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs) against DS-2741a (Part 3)</measure>
    <time_frame>Day 1 (pre-dose),Day 7 (pre-dose), Day 14 (pre-dose), Day 21 (pre-dose), Day 49, Day 63</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Part 1: DS-2741a Cohort 1, 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 5 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: DS-2741a Cohort 2, 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 15 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: DS-2741a Cohort 3, 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 50 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: DS-2741a Cohort 4, 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 150 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: DS-2741a Cohort 5, 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 500 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: DS-2741a Cohort 6, 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive a single, subcutaneous injection of DS-2741a 1000 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive a single, subcutaneous injection of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: DS-2741a Cohort 1, X mg (based on results of Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single, subcutaneous injection of DS-2741a X mg, where X mg will be based on the maximum tolerated dose identified in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: DS-2741a Cohort 1, Y mg (based on results of Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single, subcutaneous injection of DS-2741a Y mg, where Y mg will be based on the maximum tolerated dose identified in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: DS-2741a Cohort 1, Z mg (based on results of Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive a receive a single, subcutaneous injection of DS-2741a Z mg, where Z mg will be based on the maximum tolerated dose identified in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive a single, subcutaneous injection of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-2741a</intervention_name>
    <description>Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks</description>
    <arm_group_label>Part 1: DS-2741a Cohort 1, 5 mg</arm_group_label>
    <arm_group_label>Part 1: DS-2741a Cohort 2, 15 mg</arm_group_label>
    <arm_group_label>Part 1: DS-2741a Cohort 3, 50 mg</arm_group_label>
    <arm_group_label>Part 1: DS-2741a Cohort 4, 150 mg</arm_group_label>
    <arm_group_label>Part 1: DS-2741a Cohort 5, 500 mg</arm_group_label>
    <arm_group_label>Part 1: DS-2741a Cohort 6, 1000 mg</arm_group_label>
    <arm_group_label>Part 2: DS-2741a Cohort 1, X mg (based on results of Part 1)</arm_group_label>
    <arm_group_label>Part 2: DS-2741a Cohort 1, Y mg (based on results of Part 1)</arm_group_label>
    <arm_group_label>Part 3: DS-2741a Cohort 1, Z mg (based on results of Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single, subcutaneous injection administered weekly for 4 weeks</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_label>Part 3: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Part 1 and Part 3:

               -  Japanese healthy male subjects.

               -  Age ≥20 and ≤45 years upon providing informed consent.

               -  Body mass index (BMI) ≥18.5 and &lt;25.0 kg/m^2 at screening.

          -  For Part 2:

               -  Japanese Male or female, Age ≥20 upon providing informed consent.

               -  Diagnosed with chronic atopic dermatitis (AD) at least 3 years before screening
                  and by the criteria of Hannifin and Rajka at screening.

        Exclusion Criteria:

          -  For Part 1 and Part 3:

               -  Having a history of atopic dermatitis

               -  Having a history of hypersensitivity to drugs or other substances or being
                  idiosyncratic

               -  Having alcohol or drug dependence, etc.

          -  For Part 2:

               -  Having an active dermatological disease other than AD, which, in the
                  investigator's opinion, would affect study assessments.

               -  Having a history of serious disease in the study potentially endangering the
                  participant, as judged by the investigator or sub-investigator.

               -  Having a chronic or acute infection requiring treatment within 28 days before
                  screening.

               -  Having superficial skin infections within 7 days before screening.

               -  Having a history of recurrent oral herpes and recurrent genital herpes.

               -  Having a history of parasitic infection or invasive, opportunistic infection such
                  as histoplasmosis despite infection resolution, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daiichi Sankyo Contact for Clinical Trial Information</last_name>
    <phone>+81-3-6225-1111(M-F 9-5 JST)</phone>
    <email>dsclinicaltrial@daiichisankyo.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka Pharmacology Clinical Research Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>DS-2741a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://www.vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

